731 results about "Rectal carcinoma" patented technology

The invention discloses an interpretability analysis and decision sharing verification method and system for a rectal cancer prognosis model, and relates to the field of medical artificial intelligence interpretability. The method comprises the following steps: carrying out gradient weighting class activation mapping analysis on a prognosis model to generate an image thermodynamic diagram; calculating the contribution degree of the multi-modal features by using an SHAP interpreter; an integrated visual interface is constructed, and patient data, model prediction and the explanation result are presented to a doctor together; the doctor performs independent risk assessment based on the interface information; finally, decisions of doctors and the model are compared, and model auxiliary efficiency is evaluated. Through a doctor-model decision sharing verification mechanism which is explained and innovated in a multi-level mode, the transparency and clinical credibility of the complex AI prognosis model are remarkably improved, the value of time sequence data in dynamic risk assessment can be verified, and clinical landing application of the AI model is powerfully promoted.

The invention belongs to the technical field of nuclear medicine molecular diagnosis and treatment, and discloses a modified CAIX targeting cyclic peptide, a nuclide marker and application of the modified CAIX targeting cyclic peptide in tumor diagnosis and treatment. According to the CAIX targeted cyclic peptide, a rigid bifunctional chelating agent RESCA is introduced to replace a traditional chelating agent, and a sulfonated or alkylated amino acid connector is combined, so that the enzymolysis resistance and in-vivo stability of the probe are remarkably improved. By optimizing the structure of the connector, the lipophilicity is reduced, liver and gall metabolism and non-specific uptake are reduced, and the high uptake rate of tumor target tissues is maintained. The therapeutic nuclide marker of the cyclopeptide can be used for intratumoral irradiation therapy using DOTA or NOTA in combination with an alkylated amino acid linker or an albumin ligand. Experiments show that the marker has high radiochemical purity, excellent pharmacokinetic characteristics and low kidney retention, and is suitable for precise diagnosis and targeted therapy of CAIX high expression tumors such as kidney cancer, colorectal cancer and brain glioma.

The invention provides a rectal cancer patient management method and system based on postoperative rehabilitation data analysis, and relates to the field of postoperative rehabilitation management. And executing cross-scene associated feature anomaly recognition to extract a sensitive feature variable set as observation input of the hidden Markov model, driving a rehabilitation stage transition probability to calculate and output a state anomaly feature combination, comparing and positioning a real-time rehabilitation state, calculating and outputting a dynamic rehabilitation stage switching time window, and sending the dynamic rehabilitation stage switching time window to a medical end screen display. The technical problems in the prior art that rehabilitation stage division is extensive, rehabilitation stage switching prediction precision of individual users is insufficient, and rehabilitation management suitability is affected are solved. The technical effects of eliminating the rehabilitation stage division lag effect, performing rehabilitation stage switching accurate prediction and providing high-reliability time sequence feature support for rehabilitation management are achieved.

The invention discloses a rectal cancer tumor T stage differentiation labeling method based on an enhanced CT image, and relates to the field of medical image data processing, and the method comprises the following steps: a standardized manual labeling module which is used for constructing three-dimensional pixel-level labeling data of a rectal cancer tumor T stage according to a medical image and a pathological stage standard; the data set construction module is used for uniformly storing and organizing the original CT image, the annotation mask file and the matched label description document to form a structured data set which can be used for modeling; according to the rectal cancer tumor T-stage differentiation labeling method based on the enhanced CT image, a high-quality and standardized three-dimensional T-stage labeling data set is constructed, a three-dimensional pixel-level stage labeling process for the rectal cancer enhanced CT image is provided based on the AJCC eighth version tumor stage standard, the labeling content covers tumor focuses and normal intestinal wall structures around the tumor focuses, and the three-dimensional T-stage labeling data set is established. A plurality of high-annuity imaging department doctors perform independent blind marking, expert re-checking, quality rating and the like.

The invention belongs to the technical field of biological medicines, and particularly discloses an alkynyl pyrimidine derivative as well as a preparation method and application thereof. The structure of the alkynyl pyrimidine derivative is shown as a formula I. The novel alkynyl pyrimidine derivative capable of efficiently inhibiting the LSD1 activity is provided, the preparation process is simple and easy to implement, the good effect of resisting colorectal cancer cell proliferation is shown on the animal level, and safe and effective candidate drug molecules are provided for targeted therapy of colorectal cancer.

Disclosed herein are systems, methods, and compositions for treating a subject diagnosed with, or suffering from cancer. In some embodiments, the method comprises determining whether a tumor sample from the subject includes a cytotoxic gene signature, and treating the subject based on the determination. In some embodiments, the subject has or is suspected of having a loss of heterozygosity in human leukocyte antigen (HLA) class I genes. In some embodiments, the therapy comprises one or more checkpoint inhibitors. In some embodiments, the cancer is colorectal, uterine, stomach, lung, skin, head or neck, or non-small cell lung carcinoma.

The invention discloses a phosphorylated peptidomimetic compound and a medical application thereof. The invention provides a phosphorylated peptidomimetic compound with a novel structure. Activity research shows that the phosphorylated peptidomimetic compound has excellent Cbl-b inhibitory activity and is an effective Cbl-b inhibitor. Technicians in the field know that Cbl-b overexpression can inhibit T cell immune response, and inhibition of Cbl-b can activate killing of an immune system on tumor cells. Therefore, the phosphorylated peptidomimetic compound or pharmaceutically acceptable salts and solvates thereof provided by the invention can be developed and prepared into drugs for treating diseases (such as non-small cell lung cancer, breast cancer, prostate cancer, head and neck squamous cell carcinoma, liver cancer, pancreatic cancer, colorectal cancer, ovarian cancer and other tumors) treated or relieved by inhibiting Cbl-b (such as non-small cell lung cancer, breast cancer, prostate cancer, head and neck squamous cell carcinoma, liver cancer, pancreatic cancer, colorectal cancer, ovarian cancer and the like) the medicine prospect is promising.

The invention discloses a longitudinal CT image-assisted rectal cancer neoadjuvant radiotherapy and chemotherapy treatment reaction evaluation device, which comprises a focus area segmentation module, a rectum focus area detection module, a rectum focus area detection module, a rectum focus area detection module, a rectum focus area detection module, a rectum focus area detection module, a rectum focus area detection module, a rectum focus area detection module and a rectum focus area detection module, obtaining a standardized three-dimensional tumor area; a feature fusion module extracts deep learning features of a focus area after segmentation at two time points before neoadjuvant radiotherapy and chemotherapy and before an operation from the three-dimensional tumor area, and performs weighted fusion on the deep learning features at the two time points through a dynamic attention weight layer to obtain longitudinal comprehensive features representing tumor treatment response changes; and the prediction module fuses the longitudinal comprehensive characteristics and clinical baseline data to construct a multi-modal prediction model, and outputs a treatment response prediction result of the rectal cancer patient on neoadjuvant chemoradiotherapy, so that the prediction accuracy of pathological complete remission of the rectal cancer patient can be improved, and the prognosis of the patient and the utilization efficiency of medical resources can be improved.

The invention discloses a marker for early colorectal neoplastic lesion diagnosis and application, and belongs to the technical field of biological medicine. Aiming at the problems of low colonoscopy coincidence rate of colorectal cancer patients at present and limited sensitivity and specificity of existing biomarker diagnosis, LncRNA sequencing research is combined with expanded sample verification to obtain high-specificity and high-sensitivity LncRNA which is highly related to colorectal neoplastic lesions (including adenoma and colorectal cancer), the LncRNA is specifically LOC401585, and the LncRNA has the advantages of high specificity, high sensitivity, high specificity and high sensitivity and can be used for detecting colorectal neoplastic lesions (including adenoma and colorectal cancer). The diagnosis efficacy AUC of the LOC401585 on the adenoma and the colorectal cancer is 0.952 and 0.876 respectively. Therefore, the blood LOC401585 marker can be used for auxiliary diagnosis of colorectal neoplastic lesions, and provides data support for finding novel small molecule drugs with potential treatment value.

The invention discloses an application of 2, 3-dihydroxybenzoic acid in preparation of an antitumor drug. Researches find that 2, 3-dihydroxybenzoic acid can inhibit proliferation, migration and invasion of colorectal cancer cells in vitro and promote cell cycle arrest and cell apoptosis, and 2, 3-dihydroxybenzoic acid can inhibit growth of mouse transplanted tumors in vivo and promote cell apoptosis; the 2, 3-dihydroxybenzoic acid has a remarkable treatment effect on mouse colon cancer and can improve the immunotherapy effect; moreover, the 2, 3-dihydroxybenzoic acid small molecule substance, as an inhibitor of fatty acid synthase (FASN), plays an important role in inhibiting colorectum.

The invention discloses a colorectal cancer Septin9 gene methylation detection kit based on a graded anchoring probe, and belongs to the technical field of molecular diagnosis. The graded anchoring probe is composed of a specific capture probe (F1), a precise anchoring probe (R1), a synergistic blocking probe (F2 / R2) and a short chain complementary sequence (S1) which are Septin9 methylation specific probes and can be fixed in a conical pore channel of a nuclear track membrane in a graded manner to form a capture-anchoring-blocking functional chain; during application, a general accumulation body is formed by combining with a Septin9 methylation target, a nuclear track membrane pore channel is blocked, current drop is caused, and detection is realized. Through cooperation of the probe, the nuclear track membrane and the electrochemistry, the problems of insufficient sensitivity, poor stability and poor specificity of traditional detection are solved, and the kit is suitable for ultra-early diagnosis of colorectal cancer.

The invention belongs to the technical field of biological medicines, and particularly discloses a pyrimidine derivative as well as a preparation method and application thereof. The structure of the pyrimidine derivative is as shown in formula I in the specification. The novel pyrimidine derivative capable of efficiently inhibiting the LSD1 activity is provided, the preparation process is simple and easy to implement, the good effect of resisting colorectal cancer cell proliferation is shown on the animal level, and safe and effective candidate drug molecules are provided for targeted therapy of colorectal cancer.

The invention relates to the technical field of bioinformatics and medical artificial intelligence data processing, in particular to a colorectal cancer risk assessment system based on intestinal microbiological diversity, which comprises a multi-modal time sequence data acquisition module, a multi-modal time sequence data acquisition module, a target object microbiome time sequence feature data acquisition module and a target object microbiome time sequence feature data acquisition module, obtaining current medical resource load state parameters; the compliance entropy calculation module is used for resolving longitudinal compliance entropy representing the data uploading continuity willingness of the target object; the artifact interference identification module is used for generating a physiological disturbance probability value and a denoised pathological evolution feature vector; the double-constraint risk assessment module is used for calculating an initial pathological risk index of the target object; the dynamic decision scheduling module is used for determining a final dynamic intervention strategy for the target object; according to the method, the false positive and false alarm rate is remarkably reduced, and the technical pain point that real pathological evolution and environmental interference are difficult to distinguish by a traditional method is solved.

The invention discloses application of an ENOPH1 gene, and relates to the technical field of biological medicines. According to the application, a key metabolic gene closely related to CRC prognosis is analyzed and identified by adopting bioinformatics, and the expression of ENOPH1 in KRAS mutant CRC tissues and cell lines is evaluated. The function of the ENOPH1 in the KRASG12D / G13D mutant CRC is verified through CCK8, a wound healing experiment, an in-vivo subcutaneous xenotransplantation tumor model and other in-vitro experiments. The result shows that the ENOPH1 is highly expressed in the KRAS mutant CRC and is subjected to MEK / ERK signal cascade regulation and control. The ENOPH1 is knocked down through shRNA, so that CRC cell proliferation, migration and tumorigenesis can be inhibited, cell apoptosis is induced, and the reaction to chemotherapy is enhanced. The application provides a new strategy and direction for treatment of colorectal cancer, has extremely high clinical application value, and can bring a better treatment effect for patients with colorectal cancer.

The invention discloses a medicine screening method based on colorectal cancer organoid, which comprises the following steps: adding a colorectal cancer culture medium into the cultured colorectal cancer organoid, culturing for 48-72 hours, adding a to-be-detected colorectal medicine, continuously culturing for 72-96 hours, detecting the cell activity, and screening the medicine capable of reducing the cell activity. According to the method, the tumor microenvironment of the organoid is utilized, the modeling period is shortened, the cost is reduced, the tumor state can be simulated, high-throughput drug screening can be carried out in vitro, and the method has important significance on accurate treatment of lung cancer.

The invention discloses a novel tRNA (transfer ribonucleic acid) derived small RNA biomarker tRF5-23-GlyTCC-2 and application thereof, and relates to the technical field of biological medicines. The nucleotide sequence of the biomarker tRF5-23-GlyTCC-2 disclosed by the invention is as shown in SEQ ID NO. 1, and the nucleotide sequence of the biomarker tRF5-23-GlyTCC-2 is as shown in SEQ ID NO. Results of embodiments show that the gene has significant low expression in colorectal cancer tissues and serum, when the gene is independently used for colorectal cancer diagnosis, AUC for distinguishing a patient from a healthy control reaches 0.8628, the sensitivity is 74%, the specificity is 92%, and the AUC, the sensitivity and the specificity are both superior to CEA; the AUC is improved to 0.9077 and the sensitivity reaches 90% when the compound is used in combination with CEA (Carcino Embryonic Acid). Meanwhile, low expression of the marker is related to poor prognosis characteristics such as late T staging and low differentiation of a patient, and the marker can be used for prognosis evaluation. Functional experiments prove that overexpression can inhibit colorectal cancer cell proliferation and tumor growth, and a new scheme is provided for colorectal cancer diagnosis and treatment.

Methods of treating colon cancer with antibodies that specifically bind to human cytotoxic T-lymphocyte antigen 4 (CTLA-4) are provided.

The present application belongs to the technical field of ostomy base plate, and particularly relates to a leakage-proof ostomy base plate for postoperative colorectal cancer, which comprises a suction cup, the upper side wall of the suction cup is fixedly connected with a connecting cylinder, the outer wall of the connecting cylinder is fixedly sleeved with two limiting rings matched with an ostomy bag, the outer wall of the suction cup is fixedly sleeved with an adhesive layer, the inner wall of the connecting cylinder is fixedly connected with an elastic film, and a center hole is formed in the center position of the elastic film. Before the ostomy base plate is used, the size and shape of the center hole of the ostomy base plate can be freely adjusted according to the use condition, so that the leakage risk of excrement caused by the size deviation of the manually cut traditional fixed circular center hole is avoided, the compression damage of the ostomy mucosa caused by the too small cutting is eliminated, the sealing property of the base plate and the skin around the ostomy is improved, the complications such as fecal dermatitis are reduced, the nursing operation difficulty is reduced, and the wearing comfort and the life quality of the patient are improved.

A group of diagnostic biomarkers usable for diagnosis of colorectal cancer or advanced colorectal adenoma (CRC / ACRA) is provided. The method for detecting CRC / ACRA using the group of diagnostic biomarkers is also provided. For example, the method is a non-invasive approach that may utilize serum samples for detecting colorectal cancer. Moreover, the method for detecting colorectal cancer may detect colorectal cancer of different stages (e.g., pre-cancer stage, early stage, middle stage, late stage). A kit for detecting CRC / ACRA is also provided.

This invention relates to a method for detecting colorectal cancer tumor cell-associated microorganisms, specifically a method for eliminating intestinal fecal microbial contamination and detecting colorectal cancer tumor-associated microorganisms, belonging to the field of biotechnology. This invention initially eliminates fecal microbial contamination from the sample structure by coarsely shearing and enzymatically digesting the intestinal folds and villi; then, it uses a 40μm cell sieve to filter out incompletely digested tissue fragments, further eliminating intestinal fecal bacteria contamination, and collecting a single-cell suspension; subsequently, the collected single-cell suspension is repeatedly washed with 300g centrifugation to remove as many intercellular or loosely bound "transient bacteria" as possible, retaining intracellular and firmly colonized microorganisms. Ultimately, this eliminates the severe contamination from the large and complex fecal microorganisms, allowing the detection of tumor cell-associated microorganisms, which are already present in low biomass. This method is suitable for detecting microorganisms in gastrointestinal tissues that are in direct contact with the environment.

The present application relates to a kind of anaphalis contorta exosome extraction method and its application.The exosome is obtained by ultra-high speed centrifugation method from fresh anaphalis contorta, particle size is 160-200 nm, Zeta potential is-21.63±1.34 mV, with double membrane structure, mainly containing protein (such as resveratrol O-methyltransferase etc.) and phospholipid, polysaccharide content is only 12.5% of anaphalis contorta fresh medicine, and does not contain traditional active ingredient anaphalis contorta glycoside.Experiments show that anaphalis contorta exosome can be targeted to enrich in colorectal tissue, significantly improve AOM / DSS induced colorectal cancer model mouse tumor microenvironment, reduce tumor number, regulate T cell and macrophage ratio, and relieve pathological damage, better than anaphalis contorta fresh medicine.The mechanism is related to protein component, not polysaccharide or small molecule component.The anaphalis contorta exosome provided in the present application has simple preparation process, high safety, and has significant anti-colorectal cancer application potential.

The application discloses application of a chiral tetrahydropyrazolo[1,5-a]pyrimidine derivative in preparation of an antitumor drug for treating HER2 positive colorectal cancer. Through in vitro and in vivo experiments, it is confirmed that the compound has a significant inhibitory effect on proliferation and migration of HER2 positive colorectal cancer cells, and shows antitumor activity. The application provides a new idea for developing a novel tyrosine kinase inhibitor for treating HER2 positive colorectal cancer in clinic.

The invention discloses a system and equipment for predicting colorectal cancer and progression thereof. Based on the found expression level difference of AXIN2 and / or EPHB2 in colorectal cancer and the progression thereof, the invention provides a colorectal cancer and progression prediction method, system and equipment, a computer readable storage medium and a computer program product, high-risk groups can be efficiently and accurately screened out from common groups, and colonoscopy is further completed in time. While the economic burden caused by endoscopic screening is relieved, patients suffering from colorectal adenoma and early colorectal cancer are screened out, and the method has great significance in early diagnosis and treatment of colorectal tumor and further remarkable reduction of the morbidity and mortality of colorectal cancer.

The present invention relates to compounds of formula (I), and stereoisomers, tautomers, N- oxides, and pharmaceutically acceptable salts thereof that are useful for modulating, preferably inhibiting three-prime repair exonuclease (TREX1). The present invention further relates to compounds of formula (I) for use as a medicament and to pharmaceutical compositions comprising said compounds. Further, the present invention relates to compounds of formula (I) and pharmaceutical compositions comprising said compounds for use in the treatment of cancer, such as breast, small cell lung cancer and colorectal cancer, in particular cancers with chromosomal instability, TREX1-mediated autoimmune diseases, inflammatory myocarditis, Aicardi-Goutières syndrome (AGS), familial chilblain lupus (FCL), systemic lupus erythematosus (SLE) and retinal vasculopathy with cerebral leukodystrophy (RVCL).

Provided include methods, compositions and kits for treating metastatic cancer in a subject. The method can comprise administering to a metastatic colorectal cancer patient an effective amount of a PLK1 inhibitor (for example, onvansertib) and an effective amount of bevacizumab, wherein the patient has not received any treatment comprising bevacizumab within at least three months prior to the administration of the PLK1 inhibitor and bevacizumab in a manner sufficient to reduce or inhibit progression of the metastatic cancer.

This invention belongs to the field of biomedical technology, specifically relating to a colorectal cancer antibody and its applications. The antibody is composed of a camel-derived VHH-3 single-domain antibody and a membrane-penetrating peptide TAT fused together via a flexible linker peptide (GGGGS)3, and its amino acid sequence is shown in SEQ ID NO:9. This invention uses phage display technology to screen for high-affinity VHH-3 (KD=0.9524 nM) and further constructs the membrane-penetrating nanobody TAT-VHH-3, achieving soluble and efficient preparation using a prokaryotic expression system. Experiments confirm that TAT-VHH-3 can significantly inhibit the proliferation (CCK-8 assay) and migration (scratch assay) of colorectal cancer Caco-2 cells in a concentration-dependent manner. The nanobody of this invention has advantages such as small molecular weight (approximately 16.1 kDa), strong penetrability, and high stability, providing a novel tool for tumor therapy targeting CaMKⅡα.

The present invention relates to the treatment of cancer, including colorectal cancer (CRC), by inhibiting or blocking Annexin 1. The present invention also relates to the prevention of CRC in high risk patients by inhibiting or blocking Annexin A1. The present invention also relates to the reduction of chemotherapy resistance by inhibiting or blocking Annexin A1. The present invention also relates to the detection of poor prognosis in subjects with CRC by detecting or measuring the expression level of ANXA1 and / or the protein level of Annexin 1.

The present application relates to the field of polymer chemistry and biomedical technology, and particularly relates to a macrocyclic lactone polymer shown in formula (I) which is used for preventing or treating hyperproliferative diseases, including liver cancer, leukemia, breast cancer, colon adenocarcinoma, gastric cancer, lung cancer, Barrett's esophageal cancer, cervical cancer, pancreatic cancer, endometrial cancer, bone cancer, lymphoma, kidney cancer, brain cancer, nerve cancer, nasopharyngeal cancer, oral cancer, bladder cancer, colorectal cancer and melanoma, and has the potential to be developed into a new type of antitumor drug.

In various aspects and embodiments, the Disclosure provides methods for evaluating subjects for the presence or absence of colorectal neoplasms, such as colorectal cancer (CRC), colorectal adenoma (CRA), and progressive colorectal adenoma (CRAA), by metagenomic and multi-omics analysis of feces or other biological samples. In other aspects, the Disclosure provides methods for generating machine learning models or “signatures” based on metagenomic and multi-omics analysis of feces or other biological samples to evaluate subjects for the presence or absence of colorectal diseases, including but not limited to CRC, CRA, and CRAA.

A use of a pyrithione derivative in the treatment of colorectal cancer demonstrates an affinity of zinc pyrithione (ZPT), copper pyrithione (CPT) and monomeric copper pyrithione (monomeric CPT) for epigenetic modifying enzyme HSPBAP1, wherein the pyrithione derivative can effectively target the HSPBAP1 protein; moreover, in vitro migration and invasion assays were performed on various colorectal cancer cell lines, revealing that ZPT, CPT, and monomeric CPT significantly inhibit in vitro migratory and invasive capabilities of various colorectal cancer cells, thereby indicating that the pyrithione derivative has broad anti-metastatic capabilities against colorectal cancer.